J&J's Invega is first drug approved for schizoaffective disorder in US
This article was originally published in Scrip
Johnson & Johnson's Invega (paliperidone) extended-release tablets have become the first antipsychotic approved by the US FDA for the treatment of schizoaffective disorder, as monotherapy or an adjunctive to mood stabilisers and/or antidepressants.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.